{"image_id": "_page_28_Picture_15.jpeg", "image_path": "src/data/images/_page_28_Picture_15.jpeg", "ocr_text": "Over 600m\n\npeople worldwide live with\nchronic respiratory and\nimmune-mediated diseases.\n\nAstraZeneca Annual Report & Form 20-F Inf\n\n/ BioPharmaceuticals", "caption": "a woman is using a sy to a man ' s nose"}
{"image_id": "_page_36_Picture_20.jpeg", "image_path": "src/data/images/_page_36_Picture_20.jpeg", "ocr_text": "Il Discovery and early-stage\ndevelopment 40%\n\nBl Late-stage development\n60%", "caption": "a pie chart with the percentage of people who are using social media"}
{"image_id": "_page_81_Figure_3.jpeg", "image_path": "src/data/images/_page_81_Figure_3.jpeg", "ocr_text": "Gender split of Directors\n\nHf Mens\nWomen 5", "caption": "gender gender gender gender gender gender gender gender gender gender gender gender gender gender gender gender gender gender gender gender gender"}
{"image_id": "_page_38_Figure_11.jpeg", "image_path": "src/data/images/_page_38_Figure_11.jpeg", "ocr_text": "3)\n\nBf Oncology 26%\n\nIB Cardiovascular, Renal\n& Metabolism 29%\n\nBl Respiratory & Immunology 16%\nVaccine & Immune Therapies 0%\nRare Disease 19%\n\nIB Other 10%\n\n+ Includes NMEs and additional\nindications if the lead is not\nyet launched.\n\nPhase II\u2019\n\n29\n\nBf Oncology 41%\n\nBf Cardiovascular, Renal\n& Metabolism 21%\n\n8 Respiratory & Immunology 17%\nVaccine & Immune Therapies 0%\nRare Disease 14%\n\nBH Other 7%\n\n1 Includes NMEs and additional\nindications if the lead is not\nyet launched\n\nLate-stage\ndevelopment?\n\n38\n\nBf Oncology 47%\n\nBf Cardiovascular, Renal\n& Metabolism 11%\n\nBl Respiratory & Immunology 18%\nVaccine & Immune Therapies 8%\nRare Disease 16%\n\nBH Other 0%\n\n+ Includes NMEs and additional\nindications if the lead is not\nyet launched.\n\nLife-cycle management\nprojects?\n\n81\n\nfl Oncology 72%\n\nBf Cardiovascular, Renal\n& Metabolism 10%\n\nBl Respiratory & Immunology 12%\nVaccine & Immune Therapies 0%\nRare Disease 6%\n\nIB Other 0%\n\n2 Only includes major LCM projects.", "caption": "the four stages of the digital marketing strategy"}
{"image_id": "_page_0_Picture_0.jpeg", "image_path": "src/data/images/_page_0_Picture_0.jpeg", "ocr_text": "Astrazeneca?", "caption": "the logo for astazena"}
{"image_id": "_page_109_Figure_19.jpeg", "image_path": "src/data/images/_page_109_Figure_19.jpeg", "ocr_text": "Hi Performance period\nBl Deferral period\nHolding period\n\n*Half of the annual bonus is deferred for three years.\n\nSee from page 111 for further details on plan design.", "caption": "a diagram of the number of different periods"}
{"image_id": "_page_62_Figure_1.jpeg", "image_path": "src/data/images/_page_62_Figure_1.jpeg", "ocr_text": "Highlights\nFinancial performance\n\nTotal Revenue: Therapy areas\n\nOncology CVRM?\n15% 13%\ngrowth growth\n(CER: 20%) (CER: 19%)\n\nTotal Revenue: Geographical areas\n\nUS Emerging Markets\n\n47% -4%\n\ngrowth decrease\n\n(CER: 1% growth)\n\nProduct\nSales\n\n$43.0bn\n\nReported and Core\n(2021: $36.5bn)\n\nRespiratory &\nImmunology\n\n1%\n\ndecrease\n(CER: 3% growth)\n\nEurope\n\n9%\ngrowth\n(CER: 21%)\n\nCollaboration\nRevenue\n\n$1.4bn\n\nReported and Core\n(2021: $0.9bn)\n\nVaccines & Immune\nTherapies\n\n1%\ngrowth\n(CER: 8%)\n\nEstablished\nRoW\n\n22%\n\ngrowth\n(CER: 40%)\n\nOperating\nprofit\n\n$3.8bn\n\n>3x growth - Reported\n(CER: >3x)\n\n$13.4bn\n\n34% growth - Core\n(CER: 42%)\n\nRare Disease*\n\n4%\ngrowth\n(CER: 10%)\n\nEPS\n\n$2.12\n\n(2021: $0.08) - Reported\n\n$6.66\n\n(2021: $5.29) - Core\n\nOther Medicines\n\n-4%\n\ndecrease\n(CER: 5% growth)", "caption": "the global market is growing, but it ' s not going"}
{"image_id": "_page_109_Figure_6.jpeg", "image_path": "src/data/images/_page_109_Figure_6.jpeg", "ocr_text": "iN\n\nGroup scorecard 2020 PSP\nperformance performance\n\ni Achieved 92% Hi Achieved 97%\nLapsed 8% Lapsed 3%", "caption": "a graphic showing the percentage of people who have been diagnosed"}
{"image_id": "_page_81_Figure_5.jpeg", "image_path": "src/data/images/_page_81_Figure_5.jpeg", "ocr_text": "Bi British 4\ni American 3\n\nI Belgian 1\n\ni Canadian 1\n\nIf French 1\nGerman 1", "caption": "a pie chart with the percentage of the number of people in each country"}
{"image_id": "_page_18_Figure_36.jpeg", "image_path": "src/data/images/_page_18_Figure_36.jpeg", "ocr_text": "Sustainability @ Green\n\nscorecard performance? @ Amber\n719\u00b0\n2022 7/9 ry\n\n2021 10/12 e\n\n2020 13/14 e@", "caption": "a table with the number of different types of the different types of the different types of the different types of"}
{"image_id": "_page_18_Figure_33.jpeg", "image_path": "src/data/images/_page_18_Figure_33.jpeg", "ocr_text": "86%\n\n2021\n2020\n\n86%\n85%\n89%", "caption": "a bar chart with the percentage of women ' s breast cancer"}
{"image_id": "_page_16_Figure_28.jpeg", "image_path": "src/data/images/_page_16_Figure_28.jpeg", "ocr_text": "Pipeline progression events\n\n2a\n\n1 25 against our Group scorecard for", "caption": "a diagram showing the number of people who are in the same group"}
{"image_id": "_page_36_Figure_16.jpeg", "image_path": "src/data/images/_page_36_Figure_16.jpeg", "ocr_text": "NME Phase II starts/progressions\n\nNME and major LCM Phase III\ninvestment decisions\n\n23\n\n2021\n\nNME and major LCM submissions\n\n38\n\nee S coe.\n2021 27\n2020 24\nNME and major LCM approvals\n\nses\n2021 22\n2020 29", "caption": "a diagram showing the number of different types of breast cancer"}
{"image_id": "_page_5_Figure_2.jpeg", "image_path": "src/data/images/_page_5_Figure_2.jpeg", "ocr_text": "Our strategic priorities\nOur priorities reflect how we are\n\n7)\nV\n\nworking to deliver our growth\n\nthrough innovation strategy and\n\nachieve our Purpose of pushing\n\nthe boundaries of science to 1. Science and 2. Growth and 3. People and\n\ndeliver life-changing medicines. Innovation Therapy Area Sustainability\n\nLeadership\n\nScience and innovation-led Distinctive R&D capabilities\n\nWe use our distinctive scientific\n\ncapabilities to deliver a pipeline 179 1] 5 1 2 1\n\nof life-changing medicines. projects in NMEs in our NME or major LCM\nour development late-stage pipeline projects in Phase II\npipeline! and Phase III\n\nta\n\nHf Phase! { Phasel! Ml Late-stage development\n\nLife-cycle management projects\n\n1 Includes NME and major LCM projects up to launch in all applicable major markets.\n\nLeading in our Therapy Areas\nFocused on areas where we\ncan make the most meaningful\ndifference to patients.\n\nTherapy Areas\n\nOncology\nBioPharmaceuticals\nRare Disease\n\nTotal Revenue\u201d\n\n$44.4bn\n\n$26.6bn.\n\n2 Total Revenue includes revenues from Other Medicines.\nSee page 33.\n\nBroad-based, diverse\nsource of business\nDiversified portfolio across\nprimary, specialty care\nand rare disease with a\nglobal reach.\n\nTotal Revenue\nby Therapy Area\n\nBf Oncology 35%\n\nIf BioPharmaceuticals 45%\nRare Disease 16%\nOther Medicines 4%\n\nTotal Revenue\nby reporting region?\nHus 40%\n1 Emerging Markets 26%\nEurope 20%\nEstablished Rest\n\nof World 13%", "caption": "the world ' s most and most - selling companies infographic"}
